RUS 3108

Drug Profile

RUS 3108

Latest Information Update: 26 May 2009

Price : $50

At a glance

  • Originator Dr Reddys Laboratories
  • Class Antihyperlipidaemics; Cardiovascular therapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Atherosclerosis

Most Recent Events

  • 26 May 2009 Discontinued - Preclinical for Atherosclerosis in India (unspecified route)
  • 26 May 2009 Discontinued - Phase-I for Atherosclerosis in Ireland (unspecified route)
  • 07 Feb 2005 Phase-I clinical trials in Atherosclerosis in Ireland (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top